Research programme: HCV protease inhibitors - Genoscience

Drug Profile

Research programme: HCV protease inhibitors - Genoscience

Alternative Names: BL-8030; GNS 037; GNS 37; HCV NS3-4A PI - Genoscience; HCV protease inhibitors - RFS Pharma/Genoscience

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genoscience; RFS Pharma LLC - Genoscience (JV)
  • Developer Genoscience
  • Class Peptides
  • Mechanism of Action Hepatitis C protease inhibitors; Hepatitis C virus NS3 protein inhibitors; HIV fusion inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hepatitis C
  • Discontinued HIV infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-C in France
  • 10 Jun 2013 BL 8030 licensed to Jiangsu Chia-tai Tianqing Pharmaceuticals in China and Hong Kong
  • 07 Feb 2012 BL 8030 licensed to BioLineRx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top